Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy

Gut

Volumn 53, Issue 4, 2004, Pages 487-493

  Nilssen, D E ^b,c   Oktedalen O ^d   Brandtzaeg, P ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DIDANOSINE; DOXYCYCLINE; ETHAMBUTOL; FLUCONAZOLE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; NYSTATIN; PROTEINASE INHIBITOR; RIFABUTIN; STAVUDINE; TOBRAMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; B LYMPHOCYTE; BACTERIAL INFECTION; CANDIDIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DUODENUM BIOPSY; FEMALE; FLUORESCENCE MICROSCOPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; IMMUNE SYSTEM; INTESTINE BIOPSY; INTESTINE CELL; INTESTINE MUCOSA; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; MYCOSIS; PLASMA CELL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS INFECTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; BETA 2-MICROGLOBULIN; CD4 LYMPHOCYTE COUNT; DUODENUM; FEMALE; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULINS; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 1642393388     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.027854     Document Type: Article

References (35)

1. Scamurra RW, Nelson DB, Lin XM, et al. Mucosal plasma cell repertoire during HIV-1 infection. J Immunol 2002;169:4008-16.
2. + T cell help in HIV-infected individuals. Proc Natl Acad Sci USA 2003;100:6057-62.
3. Janoff EN, Jackson S, Wahl SM, et al. Intestinal mucosal immunoglobulins during human immunodeficiency virus type 1 infection. J Infect Dis 1994;170:299-307.
4. Eriksson K, Kilander A, Hagberg L, et al. Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals. AIDS 1995;9:695-700.
5. Brandtzaeg P, Farstad IN, Johansen F-E, et al. The B-cell system of human mucosae and exocrine glands. Immunol Rev 1999;171:45-87.
6. Kotler DP, Scholes JV, Tierney AR. Intestinal plasma cell alterations in the acquired immunodeficiency syndrome. Dig Dis Sci 1987;32:129-38.
7. Bishop PE, McMillan A, Gilmour HM. Immunologic study of the rectal mucosa of men with and without human immunodeficiency virus infection. Gut 1987;28:1619-24.
8. Rodgers VD, Kagnoff MF. Abnormalities of the intestinal immune response in AIDS. Gastroenterol Clin North Am 1988;17:487-97.
9. Rodgers VD, Fasset R, Kagnoff MF. Abnormalities in intestinal T cells in homosexual populations including those with the lymphadenopathy syndrome and acquired immunodeficiency syndrome. Gastroenterology 1986;90:552-8.
10. Eriksson K, Kilander A, Hagberg L, et al. Intestinal antibody responses to oral vaccination in HIV-infected individuals. AIDS 1993;7:1087-91.
11. Autran B, Carcelaint G, Li TS, et al. Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999;66:207-11.
12. Cassone A, Tacconefli E, De Bernardis F, et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral Candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002;185:188-95.
13. Mioo YM, Hayes PJ, Gotch FM, et al. Elevated mucosal addressin cell adhesion molecule-1 expression in acquired immunodeficiency syndrome is maintained during antiretroviral therapy by intestinal pathogens and coincides with increased duodenal CD4 T cell densities. J Infect Dis 2002;185:1043-50.
14. Autran B, Debré P, Walker B, et al. Therapeutic vaccines against HIV need international partnerships. Nature Rev Immunol 2003;3:503-8.
15. Nilssen DE, Müller F, Øktedalen O, et al. Intraepithelial γ/δ T cells in duodenal mucosa are related to the immune state and survival time in AIDS. J Virol 1996;70:3545-50.
16. Brinchmann JE, Vartdal F, Thorsby E. T lymphocyte subset changes in human immunodeficiency virus infection. J Acq Immun Def Syndr 1989;2:398-403.
17. Brinchmann JE, Vartdal F, Gaudernack G, et al. Direct immunomagnetic quantification of lymphocyte subsets in blood. Clin Exp Immunol 1988;71:182-6.
18. Nilssen DE, Halstensen TS, Frøland SS, et al. Distribution and phenotypes of duodenal intraepithelial γ/δ T cells in patients with various types of primary B-cell deficiency. Clin Immunol Immunopathol 1993;68:301-10.
19. Brandtzaeg P. Mucosal and glandular distribution of immunoglobulin components. Immunohistochemistry with a cold ethanol-fixation technique. Immunology 1974;26:1101-14.
20. Brandtzaeg P, Kett K, Rognum TO. Distribution of mucosal IgA and IgG subclass-producing immunocytes and alterations in various disorders. Monogr Allergy 1986;20:179-94.
21. Jefferis R, Reimer CB, Skvaril F, et al. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett 1985;10:223-52.
22. Valentijn RM, Radl J, Haaijman JJ, et al. Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int 1984;26:760-6.
23. Brandtzaeg P, Karlsson G, Hansson G, et al. The clinical condition of IgA-deficient patients is related to the proportion of IgD- and IgM-producing cells in their nasal mucosa. Clin Exp Immunol 1987;67:626-36.
24. Nilssen DE, Friman V, Theman K, et al. B-cell activation in duodenal mucosa after oral cholera vaccination in IgA deficient subjects with or without IgG subclass deficiency. Scand J Immunol 1993;38:201-8.
25. Brandtzaeg P, Baklien K, Fausa O, et al. Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis. Gastroenterology 1974;66:1123-36.
26. Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology 1987;93:919-24.
27. Nilssen DE, Brandtzaeg P, Frøland SS, et al. Subclass composition and J-chain expression of the "compensatory" gastrointestinal IgG cell population in selective IgA deficiency. Clin Exp Immunol 1992;87:237-45.
28. Schneider T, Zippel T, Schmidt W, et al. Abnormal predominance of IgG in HIV-specific antibodies produced by short-term cultured duodenal biopsy specimens from HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:333-9.
29. Schäfer F, Kewenig S, Stolte N, et al. Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques. Gut 2002;50:608-14.
30. Schneider T, Zippel T, Schmidt W, et al. Increased immunoglobulin G production by short term cultured duodenal biopsy samples from HIV-infected patients. Gut 1998;42:357-61.
31. Brandtzaeg P, Tolo K. Mucosal penetrability enhanced by serum-derived antibodies. Nature 1977;266:262-3.
32. Fernandez MI, Pedron T, Tournebize R, et al. Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells. Immunity 2003;18:739-49.
33. 2-microglobulin in acquired immunodeficiency syndrome (AIDS) patients. Clin Chem 1983;29:1560.
34. 2-microglobulin in patients with common variable immuno-deficiency or selective IgA deficiency. Int Arch Allergy Appl Immunol 1987;84:217-22.
35. 2-microglobulin in serum of IgA-deficient subjects with or without IgG subclass deficiency. Clin Exp Immunol 1993;94:91-8.